Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast CancerJosé Baselga, Federico Rojo|Journal of Clinical Oncology|2005Cited by 409
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP. Tarantino, G. Curigliano, Frédérique Penault‐Llorca et al.|Annals of Oncology|2023Cited by 298
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorU. Vanhoefer, José Baselga, Mitra Tewes et al.|Journal of Clinical Oncology|2003Cited by 259
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsRaúl Rincón, Federico Rojo|Oncotarget|2015Cited by 100
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast CancerPaula Gónzález-Alonso, Federico Rojo|Cancers|2020Cited by 37